Cas:460345-15-7 1-pentyl-3-methylimidazolium trifluoromethanesulfonate manufacturer & supplier

Chemical Name:1-pentyl-3-methylimidazolium trifluoromethanesulfonate

CAS.NO:460345-15-7

Synonyms:MFCD28016460;1-Methyl-3-pentyl-1H-imidazol-3-ium trifluoromethanesulfonate

Molecular Formula:C₁₀H₁₇F₃N₂O₃S

Molecular Weight:302.314

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:302.091187

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD28016460 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Methyl-3-pentyl-1H-imidazol-3-ium trifluoromethanesulfonate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Methyl-3-pentyl-1H-imidazol-3-ium trifluoromethanesulfonate Use and application,1-Methyl-3-pentyl-1H-imidazol-3-ium trifluoromethanesulfonate technical grade,usp/ep/jp grade.

Related News: MG is a “serious, lifelong disease with life-threatening manifestations, and most patients do not achieve treatment goals with conventional therapy,” the report said. methyl 4-[(2,3-dihydro-1H-inden-1-yl)oxy]-3,5-difluorobenzenepropanoate manufacturers ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. endo-7-chloro-1,4,4-trimethylbicyclo(3.2.0)hept-2-en-6-one suppliers The group, after examining Soliris’ late-stage trial data, determined they’re highly certain it produces a small benefit to patients who are positive for anti-AChR antibodies, while there’s a “moderate certainty of a small or substantial net health benefit.” L-Histidine, (4R)-1-([1,1′-biphenyl]-4-ylsulfonyl)-4-hydroxy-L-prolyl- vendor & factory The review considered two cases of AML in patients treated with an investigational medicine, bb1111, in a clinical trial for sickle cell disease. Although there have been no reports of AML with Zynteglo, both medicines use the same viral vector and there was a concern that the vector may be implicated in the development of the cancer (insertional oncogenesis).,(For more on Stevanato, see The Covid Vaccine Will Require Billions Of Tiny Glass Vials—And This Italian Billionaire Family Is Making Them.)